On April 14, 2023 Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, reported the company will present one poster concerning Phase 1 clinical results for BAT1006 at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – April 19, 2023 in Orlando, Florida (Press release, BioThera Solutions, APR 14, 2023, View Source [SID1234630108]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, entitled "A Phase I study of BAT1006, a Novel Anti-HER2 Antibody, in Patients with Locally Advanced/Metastatic Solid Tumors," will highlight Phase I clinical data demonstrating the safety and efficacy of BAT1006 in HER2-positive cancer patients. An abstract of the presentation will be available on AACR (Free AACR Whitepaper) website on the day of the presentation.
Presentation details are as follows:
Session Title:
Phase I Clinical Trials
Session Time:
Tuesday Apr 18, 2023 9:00 AM – 12:30 PM
Location:
Orange County Convention Center, Poster Section 46
Poster Board Number:
2
Abstract Number:
CT189
Copies of the poster will be made available on the Company’s website after they are presented.
About BAT1006
BAT1006 is a HER2 extracellular domain II-targetd monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) effect aiming for HER2-positive locally advanced/metastatic solid tumors. After the dose escalation trial, dose expansion study of BAT1006 and combination therapy with other HER2-based therapy such as BAT8010 ADC will be initiated for the treatment of HER2-positive cancers.